Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Premature atherosclerosis in patients with acquired immunodeficiency syndrome.

Zeng Y, Ye YC, Luo L, Qiu ZF, Han Y, Li XM, Fang Q, Zhang SY, Li TS.

Chin Med J (Engl). 2010 Dec;123(23):3396-9.

2.

Increased arterial stiffness in HIV-infected children: risk factors and antiretroviral therapy.

Charakida M, Loukogeorgakis SP, Okorie MI, Masi S, Halcox JP, Deanfield JE, Klein NJ.

Antivir Ther. 2009;14(8):1075-9. doi: 10.3851/IMP1437.

PMID:
20032537
3.

Aortic stiffness in untreated adult patients with human immunodeficiency virus infection.

Schillaci G, De Socio GV, Pucci G, Mannarino MR, Helou J, Pirro M, Mannarino E.

Hypertension. 2008 Aug;52(2):308-13. doi: 10.1161/HYPERTENSIONAHA.108.114660. Epub 2008 Jun 16.

4.

Functional and structural markers of atherosclerosis in human immunodeficiency virus-infected patients.

van Wijk JP, de Koning EJ, Cabezas MC, Joven J, op't Roodt J, Rabelink TJ, Hoepelman AM.

J Am Coll Cardiol. 2006 Mar 21;47(6):1117-23. Epub 2006 Feb 23.

5.
6.

Arterial stiffness and carotid intima-media thickness in HIV infected patients.

Papita A, Albu A, Fodor D, Itu C, Cârstina D.

Med Ultrason. 2011 Jun;13(2):127-34.

7.

Impact of treatment with protease inhibitors on aortic stiffness in adult patients with human immunodeficiency virus infection.

Schillaci G, De Socio GV, Pirro M, Savarese G, Mannarino MR, Baldelli F, Stagni G, Mannarino E.

Arterioscler Thromb Vasc Biol. 2005 Nov;25(11):2381-5. Epub 2005 Aug 25.

8.

Potent antiretroviral therapy for human immunodeficiency virus infection increases aortic stiffness.

Eira M, Bensenor IM, Dorea EL, Cunha RS, Mill JG, Lotufo PA.

Arq Bras Cardiol. 2012 Dec;99(6):1100-7. Epub 2012 Nov 30. English, Portuguese.

9.

Pulse wave velocity as index of arterial stiffness in HIV-infected patients compared with a healthy population.

Echeverría P, Bonjoch A, Moltó J, Jou A, Puig J, Ornelas A, Pérez-Álvarez N, Clotet B, Negredo E.

J Acquir Immune Defic Syndr. 2014 Jan 1;65(1):50-6. doi: 10.1097/QAI.0b013e3182a97c17.

PMID:
23982659
10.

Is moderate HIV viremia associated with a higher risk of clinical progression in HIV-infected people treated with highly active antiretroviral therapy: evidence from the Italian cohort of antiretroviral-naive patients study.

Murri R, Lepri AC, Cicconi P, Poggio A, Arlotti M, Tositti G, Santoro D, Soranzo ML, Rizzardini G, Colangeli V, Montroni M, Monforte AD; ICoNA Study Group.

J Acquir Immune Defic Syndr. 2006 Jan 1;41(1):23-30.

PMID:
16340469
11.

Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.

PMID:
11826235
12.
13.

CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.

McDermott AY, Terrin N, Wanke C, Skinner S, Tchetgen E, Shevitz AH.

Clin Infect Dis. 2005 Dec 1;41(11):1662-70. Epub 2005 Oct 19.

14.

Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.

Jevtović DO, Salemović D, Ranin J, Pesić I, Zerjav S, Djurković-Djaković O.

HIV Med. 2007 Mar;8(2):75-9.

15.

Impact of highly active antiretroviral therapy on blood pressure in HIV-infected patients. A prospective study in a cohort of naive patients.

Palacios R, Santos J, García A, Castells E, González M, Ruiz J, Márquez M.

HIV Med. 2006 Jan;7(1):10-5.

16.

Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use.

Kwong GP, Ghani AC, Rode RA, Bartley LM, Cowling BJ, da Silva B, Donnelly CA, van Sighem AI, Cameron DW, Danner SA, de Wolf F, Anderson RM.

AIDS. 2006 Oct 3;20(15):1941-50.

PMID:
16988515
17.

Immunologic response to antiretroviral therapy in hepatitis C virus-coinfected adults in a population-based HIV/AIDS treatment program.

Braitstein P, Zala C, Yip B, Brinkhof MW, Moore D, Hogg RS, Montaner JS.

J Infect Dis. 2006 Jan 15;193(2):259-68. Epub 2005 Dec 7.

18.

Cerebrovascular ischemic events in HIV-1-infected patients receiving highly active antiretroviral therapy: incidence and risk factors.

Corral I, Quereda C, Moreno A, Pérez-Elías MJ, Dronda F, Casado JL, Muriel A, Masjuán J, Alonso-de-Leciñana M, Moreno S.

Cerebrovasc Dis. 2009;27(6):559-63. doi: 10.1159/000214219. Epub 2009 Apr 24.

PMID:
19390181
19.

Protease inhibitor treatment effect on aortic stiffness in normotensive patients with human immunodeficiency virus infection.

Lopez-Sublet M, Honoré P, Bentata M, Bratis C, Rouges F, Krivitzky A, Dhôte R, Mourad JJ.

J Mal Vasc. 2012 Jul;37(4):179-85. doi: 10.1016/j.jmv.2012.05.001. Epub 2012 Jun 13.

PMID:
22698629
20.

Is the atherosclerotic process accentuated under conditions of HIV infection, antiretroviral therapy, and protease inhibitor exposure? Meta-analysis of the markers of arterial structure and function.

Sun D, Wu Y, Yuan Y, Wang Y, Liu W, Yang J.

Atherosclerosis. 2015 Sep;242(1):109-16. doi: 10.1016/j.atherosclerosis.2015.06.059. Epub 2015 Jul 9. Review.

PMID:
26188532
Items per page

Supplemental Content

Write to the Help Desk